With AstraZeneca since 2018, Sarah leads a global team covering CMC regulatory strategy for development and pre-approval health authority submissions, serving as a key contributor to initiatives including continuous manufacturing and Q12 implementation. She represents AstraZeneca in various external capacities, including PhRMA's Global Quality and Manufacturing Committee, chair of ISPE's Regulatory Steering Council, and multiple advocacy efforts (review/inspection standards, nitrosamines, and KASA/M4Q discussions).

Prior to this, she headed two offices in FDA's Office of Pharmaceutical Quality, as director of the Office of New Drug Products and simultaneously interim director of the Office of Surveillance. She contributed heavily to OPQ's strategic direction including numerous quality review, communications, and GMP/inspectional efforts. She played a key role in FDA/nonprofit interface discussions (e.g. PhRMA, ISPE, AAM) and in development of international strategy and related ICH proposals. Sarah began her FDA career in 2002.

She completed a postdoctoral fellowship at the National Institute of Health, is trained as an organic chemist and holds a PhD in organic chemistry (Oklahoma State University) and B.A. in chemistry (Earlham College).